Stocks and Investing
Stocks and Investing
Thu, January 3, 2013
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 05:49 AM ] - WOPRAI
[ 05:48 AM ] - WOPRAI
[ 05:47 AM ] - WOPRAI
[ 05:47 AM ] - WOPRAI
[ 05:46 AM ] - WOPRAI
[ 05:46 AM ] - WOPRAI
[ 05:46 AM ] - WOPRAI
[ 05:45 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Christopher Raymond Downgraded (BIIB) to Hold and Decreased Target to $166 on, Jan 3rd, 2013
Christopher Raymond of Piper Sandler, Downgraded "Biogen Inc." (BIIB) to Hold and Decreased Target from $175 to $166 on, Jan 3rd, 2013.
Christopher has made no other calls on BIIB in the last 4 months.
There are 2 other peers that have a rating on BIIB. Out of the 2 peers that are also analyzing BIIB, 0 agree with Christopher's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Christopher
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $175 on, Monday, October 8th, 2012
- Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $160 on, Thursday, September 6th, 2012